It is my pleasure to introduce this peer-reviewed EHA 2024 Medicom Conference Report. The annual EHA meeting is still growing. This year’s number of attendants was 15.000 in person and another 2.000 virtually. The Scientific Program Committee of the EHA has taken care of what, in my opinion, turned out to be a wonderful programme.
From this year’s EHA, we selected several interesting abstracts that will likely change your practice now or soon. The abstracts are summarised in a way that the information is easy to digest in a rather short time.
The number of new drugs steadily increases, resulting in a better prognosis for many haematological diseases. Many new combinations of these drugs were discussed during the meeting.
The increase in abstracts focussing on immunotherapy including bispecific antibody and CAR T-cell treatment applied in a variety of haematological malignancies, which we have observed at previous meetings, was maintained in this year’s event. New treatments for haemoglobinopathies and haemophilia and other benign haematological disorders are rapidly being developed.
You will find snapshots of all these new developments in this report. I hope that these are helpful in your daily practice and I am sure you will enjoy.
Gert Ossenkoppele
Biography
Prof. Gert Ossenkoppele was appointed in 2003 as Professor of Haematology at the VU University Medical Center in Amsterdam. He obtained his doctorate of medicine at that same University in 1977. He is board-certified in Haematology and Internal medicine (1984). The title of his PhD thesis (1990) was: “Differentiation induction in acute myeloid leukaemia (AML)”. Gert Ossenkoppele has authored over 480 publications in peer-reviewed journals and is an invited speaker at many national and international scientific meetings. His research interests are mainly translational and include the (stem cell) biology of AML/myelodysplastic syndrome (MDS), leukaemic stem cell target discovery, immunotherapy, and measurable residual disease (MRD) detection using flow cytometry to inform treatment of AML/MDS. He was the PI of national and international clinical trials in myeloid malignancies. He was associate editor of HemaSphere, the official journal of EHA and the European Journal of Haematology and regularly reviewed for many high-standard haematological journals (Blood, Leukemia, JCO, Haematologica, Oncotarget, NEJM). He recently rotated off as chair of the AML working party of HOVON (Dutch-Belgian Hematology Trial Group) and is past vice-chair of the HOVON Executive Board. He rotated off in 2024 as a lead participant of the AML Work package of the European LeukemiaNet (ELN) as well as a board member of the ELN foundation. He is the key opinion leader of WP2 AML of the HARMONY project. He rotated off as a board member of the European Haematology Association (EHA) and was chair of the EHA Educational Committee. He further rotated off as chair of the Global and EU steering committee of the AMLGlobalPortal an educational portal for haematologists (www.amlglobalportal.com).
Recently he retired and now functions as emeritus Professor of Haematology at the Amsterdam University, location VUmc.
In 2022 he received the Jean Bernard Lifetime Achievement Award at the EHA Annual meeting in Vienna.
Recently he stopped most of his professional activities.
Prof. Gert Ossenkoppele has no conflicts of interest to declare.
Posted on
Previous Article
« Meet the Expert: Samantha Nier on the added value of patient advocacy –not just for patients Next Article
DREAMM 8: Belantamab mafodotin offers hope for patients with RRMM »
« Meet the Expert: Samantha Nier on the added value of patient advocacy –not just for patients Next Article
DREAMM 8: Belantamab mafodotin offers hope for patients with RRMM »
Table of Contents: EHA 2024
Featured articles
Meet the Expert: Prof. C. Ola Landgren discusses MRD as a key endpoint in haematological cancer trials
Multiple Myeloma
Isa-VRd proves its value in newly diagnosed MM in the IMROZ trial
PERSEUS: High MRD negativity rates with D-VRd and consolidation therapy and D-R maintenance in MM
Post-intensification data confirm superiority of quadruple therapy in MM
Promising phase 1 results for novel CAR T-cell therapy in MM
DREAMM 8: Belantamab mafodotin offers hope for patients with RRMM
Leukaemia
PhALLCON: Third-generation TKI superior to first-generation TKI in Ph+ ALL
APOLLO: ATRA plus ATO meets expectations in high-risk APL
Excellent phase 3 results for asciminib in chronic myeloid leukaemia
AUGMENT-101: Revumenib trial in KMT2Ar leukaemia stopped early for efficacy
FLAG-Ida plus venetoclax induces high MRD-negativity rates in AML
CD40/CD47 inhibitor shows promise in high-risk MDS and AML
ENHANCE: Magrolimab does not ameliorate health outcomes in high-risk MDS
Can MRD-guided azacitidine treatment improve outcomes in AML and MDS?
Can WGTS replace standard-of-care diagnostics in AML?
Non-malignant Haematology
ENERGIZE: Mitapivat meets primary efficacy endpoint in thalassaemia
Sovleplenib delivers durable responses and QoL improvements in primary ITP
Avatrombopag successful in children with chronic ITP
RUBY: Promising data for first AsCas12a gene-editing therapy in sickle cell disease
Encouraging data for ELA026 to treat secondary haemophagocytic lymphohistiocytosis
Myelofibrosis
Navitoclax plus ruxolitinib leads to spleen volume reductions in myelofibrosis
Is pelabresib plus ruxolitinib the paradigm-shifting combo therapy for myelofibrosis?
Lymphoma
The landscape of TP53 mutations and their prognostic impact in CLL
Can golcadomide plus R-CHOP become the first-line standard of care in high-risk BCL?
High survival rates following atezolizumab consolidation in DLBCL
First results for zanubrutinib plus venetoclax in del(17p)/TP53-mutated CLL/SLL
EPCORE CLL-1: Promising data for epcoritamab in high-risk Richter’s transformation
Updates from the EBMT Lymphoma Working Group: outcomes after allo- and auto-SCT for T-cell lymphoma subtypes
ECHO: Can we expect a novel standard of care in newly diagnosed MCL?
Clinically meaningful outcomes for mosunetuzumab across follicular lymphoma subgroups
Related Articles
September 24, 2021
Subcutaneous epcoritamab shows promise in some non-Hodgkin lymphoma patients
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com